COMPANY

Armida Labs, Inc.

HQ: San Diego, CA source · armidalabs.com ↗

ARMIDA LABS, INC. has received NIH funding, most recently in fiscal 2026 for the project “Targeting pancreatic cancer metastases with Targefrin”. From public records Source · Oct 12, 2026

Keywords: cancer

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $1.09M (SBIR Phase II 5R44CA277917-03, continuation, notice Sep 2, 2026). NIH RePORTER 5R44CA277917-03 (Sep 2, 2026)
Evidence (1 event)
- Sep 2, 2026 · NIH RePORTER 5R44CA277917-03
  Organization: ARMIDA LABS, INC.; City/State: SAN DIEGO, CA; Project number: 5R44CA277917-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 1088000; Administering IC: National Cancer Institute; Project title: Targeting pancreatic cancer metastases with Targefrin; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Sep 2, 2026 Grant Government grant — SBIR: $1.09M (annual award, as published), announced Sep 2, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Sep 10, 2025 Grant Government grant — SBIR: $1.16M (annual award, as published), announced Sep 10, 2025. Agency: NIH/NCI. Source: government award database. source ↗

Funding

Last 2 years.

Sep 2, 2026 Government grant — SBIR: $1.09M (annual award, as published), announced Sep 2, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Sep 10, 2025 Government grant — SBIR: $1.16M (annual award, as published), announced Sep 10, 2025. Agency: NIH/NCI. Source: government award database. source ↗